Oramed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ORMP Oramed Pharmaceuticals Inc
GOTU Gaotu Techedu Inc
SGDVV Safe & Green Development Corp
GLBZ Glen Burnie Bancorp
PHAR Pharming Group NV
CARD Max Auto Industry -3X Inverse Leveraged ETN
HIW Highwoods Properties Inc
HFRO Highland Opportunities and Income Fund
HDV iShares Core High Dividend ETF
HDELY Heidelberg Materials AG

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Oramed Pharmaceuticals Inc. is a pharmaceutical company, which is engaged in the research and development of pharmaceutical solutions with its technology platform. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. It is conducting Phase III trials in patients with type 2 diabetes. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. It is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary, Oravax Medical Inc.


Last Trade
0.07 (2.66%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Target's stock snaps longest losing streak in 23 years as anti-LGBTQ+ backlash continues

12:19 pm ET June 3, 2023 (MarketWatch)

By James Rogers

Target is coming under pressure over its Pride-related merchandise.

Target Corp.'s stock is up 0.1% Friday after snapping its longest losing streak in 23 years amid an anti-LGBTQ+ backlash against the retail giant.

The stock ended Thursday's session up 0.2% to snap the losing streak. Target (TGT) shares had ended Wednesday's session down 2.2%, marking their ninth consecutive decline, and the stock's longest losing streak since an 11-day stretch that ended Feb. 24, 2000, according to Dow Jones data. Wednesday also marked the stock's lowest close since Aug. 11, 2020.

Target was downgraded to neutral from overweight Thursday by JPMorgan, which the impact of "consumer pressures and recent company controversies" about the retail giant.

Related:Target's stock, on its longest losing streak in 23 years, downgraded at JPMorgan

The company is facing an anti-LGBTQ+ backlash against its Pride collection in recent weeks. On Thursday -- the first day of Pride Month -- a group of protestors demonstrated against the Pride collection outside a Target store in midtown Miami, according to WPLG Local 10. Counter-protestors also gathered outside the store, WPLG Local 10 reports. Pride merchandise is being sold at the Target store.

Target's stock has fallen 12% in 2023, compared with the S&P 500 index's gain of 11.1%.

Related: Trans designer in Target anti-LGBTQ+ backlash says he was 'dealt the worst hand'

Of 35 analysts surveyed by FactSet, 20 have an overweight or buy rating and 15 have a hold rating for Target.

Additional reporting by Tomi Kilgore.

-James Rogers

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

June 03, 2023 12:19 ET (16:19 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.